KKKuldeepak Singh Kular

Kuldeepak Singh Kular

*This is an algorithmically generated author record based on publicly available information.

Kuldeepak Singh Kular has a total of 109 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Expert Consensus on Obesity Management Protocols – A Joint Position Statement by Obesity and Metabolic Surgery Society of India (OSSI) and Endocrine Society of India (ESI)

    by Aparna Govil Bhasker, Nitin Kapoor, Sarfaraz Baig, Chetan Parmar, Shehla Shaikh, Randeep Wadhawan, Sumeet Shah, Narendra Kotwal, Kvs Harikumar, Sambit Das, et al.

  • Surgeons’ Perspectives on Insurance Coverage for Metabolic and Bariatric Surgery in India: An Obesity and Metabolic Surgery Society of India (OSSI) Survey

    by Aparna Govil, Randeep Wadhawan, Manish Khaitan, Surendra Ugale, Abhishek Katakwar, Apoorv Srivastava, Ashish Vashistha, Gurvinder Jammu, Kuldeepak Kular, Manish Baijal, et al.

    Background Metabolic and bariatric surgery (MBS) is a proven and effective treatment for obesity and its related illnesses. In 2019, the Insurance Regulatory and Development Authority of India (IRDAI) mandated that MBS be covered under health insurance policies if specific medical criteria are met. However, real-world implementation of this policy is often inconsistent, with reports of claim denials and delays. This study aimed to assess Indian metabolic and bariatric surgeons’ experiences with insurance coverage for metabolic and bariatric surgery. Methods A cross-sectional survey was conducted among 109 members of the Obesity Surgery Society of India (OSSI) using a structured Google Form between November 2024 and March 2025. The questionnaire covered surgeon demographics, insurance experiences, patient patterns, and policy suggestions. Data were collected anonymously and analyzed using descriptive statistics. Results While 87.2% of respondents observed more patient interest after IRDAI’s insurance mandate, only 9.2% reported that most of their patients used insurance. Low awareness, complex paperwork, and high out-of-pocket costs were major problems. 95.4% said patients delay surgery while waiting for insurance approval. The approval process was rated as complex or very complex by 69.7%. High denial rates were reported, often due to obesity exclusions or incomplete documentation. Nearly all respondents supported changes to improve the system, including faster approvals, fewer documentation requirements, and broader eligibility criteria such as lower BMI thresholds and inclusion of type 2 diabetes. Conclusions Despite regulatory progress, insurance-related challenges like administrative delays, poor patient awareness, and inconsistent claim approvals continue to limit equitable access to MBS in India. Policymakers and insurers need to streamline processes and expand eligibility to ensure more people can benefit from this life-saving treatment.

  • Open Access

    Robert Rutledge: A Celebration of His Life

    by Kuldeepak S. Kular, Enrique Luque-De-León, Mervyn Deitel

  • Beyond Insulin: Modified OAGB in Low-BMI Insulin-Resistant and Non-compliant Type 2 Diabetic Patients

    by Shubhkaran Singh Gill, Naveen Manchanda, Robert Rutledge, Kuldeepak Singh Kular

    Background Metabolic surgery’s role in lower-BMI patients with type 2 diabetes mellitus (T2DM) remains debated, particularly regarding long-term outcomes. Methods This retrospective study analyzed 54 patients (BMI 24–30 kg/m2) with poorly controlled T2DM (HbA1c ≥ 10%) who underwent modified one anastomosis gastric bypass between 2016 and 2017. Primary outcomes included glycemic control, weight loss, and complications at 7 years. Results Mean preoperative BMI was 26.76 ± 1.82 kg/m2, and HbA1c was 12.63 ± 1.67%. Follow-up rates were year 1 (54/54, 100%), year 3 (52/54, 96.3%), year 5 (48/54, 88.9%), and year 7 (36/38, 94.7% of eligible patients). At 7-year follow-up, mean HbA1c decreased to 6.17 ± 0.71% (p < 0.001), and %TWL was 13.1 ± 2.4%. Complete medication elimination occurred in 45 of 54 patients (83.3%) achieving HbA1c < 6.5%. No mortality or major complications were reported. Conclusions Modified OAGB demonstrates sustained glycemic control and safety in lower-BMI patients with severe T2DM through 7 years with potential benefits of early surgical intervention.

  • Obesity and Metabolic Surgery Society of India (OSSI) Recommendations for Bariatric and Metabolic Surgery Practice During the COVID-19 Pandemic

    by Sandeep Aggarwal, Kamal Mahawar, Manish Khaitan, Praveen Raj, Randeep Wadhawan, NandaKishore Dukkipati, Kuldeepak S Kular, Arun Prasad, Aparna Govil Bhasker, Vandana Soni, et al.

    Bariatric and metabolic surgery (BMS), the only effective option for patients with obesity with or without comorbidities, has been stopped temporarily due to the ongoing novel corona virus disease (COVID-19) pandemic. However, there has been a recent change in the governmental strategy of dealing with this virus from ‘Stay at Home’ to ‘Stay Alert’ in many countries including India. A host of health services including elective surgeries are being resumed. In view of the possibility of resumption of BMS in near future, Obesity and Metabolic Surgery Society of India (OSSI) constituted a committee of experienced surgeons to give recommendations about the requirements as well as precautions to be taken to restart BMS with emphasis on safe delivery and high-quality care.


  • The Mini-Gastric Bypass original technique

    by Robert Rutledge, Kuldeepak Kular, Naveen Manchanda

    Mini-Gastric Bypass (MGB) is becoming more and more popular as shown by the numerous articles published over the past 15 years, supporting the operation as a short and simple procedure with excellent outcomes and low complication rates. There is still confusion amongst surgeons on the technique of the operation. The purpose of this paper is to review and describe the technique of MGB by its originators. With 20 years of experience of performing the original MGB, the authors present the details of the MGB. The MGB consists of a long conduit from below the crow's foot extending up to the left of the angle of His. It is similar to, but importantly, not the same as the pouch of the Sleeve Gastrectomy. MGB has a wide gastro-jejunal anastomosis to an anti-colic loop of jejunum 150-200 cm distal to the ligament of Trietz. The power of MGB comes from the fact that it is both a "Non-Obstructive" restrictive procedure and it also has a significant fatty food intolerance component with minimal malabsorption. In this article we describe the original Rutledge technique of Mini-Gastric Bypass. Notably this is neither a "Single Anastomosis bypass", nor an "Omega Loop Bypass" and also not the "One Anastomosis Bypass of Carbajo". It is a particular technique first created by Rutledge in 1997 and associated with low risk and excellent outcomes. The goal of this manuscript is to help avoid complications and problems seen when the operation deviates from some of the basic principles of general surgery used in the original operation.


  • Reply to Gagner’s Letter RE Features of MGB and OAGB

    by Mario Musella, Mervyn Deitel, K. S. Kular, Miguel-A. Carbajo, Karl P. Rheinwalt, Chetan Parmar, Arun Prasad, Enrique Luque-De-Leon, Gurvinder Jammu, Roger Luciani, et al.


  • Regarding Liver Function 1 Year After Omega Loop Gastric Bypass

    by Robert Rutledge, Mervyn Deitel, Kuldeepak S. Kular


  • Seven Years of Mini-Gastric Bypass in Type II Diabetes Patients with a Body Mass Index <35 kg/m2

    by Kuldeepak S. Kular, Naveen Manchanda, Gurpreet K. Cheema

    Mini-gastric bypass (MGB) is a safe, effective, and reversible procedure for patients with type II diabetes mellitus (T2DM) and morbid obesity. Less is known, however, about its long-term effects in patients with a body mass index (BMI) 2. From February 2007 to February 2014, 1468 patients underwent MGB at our institution, including 983 with T2DM. Of these, 128 (82 women), of mean age 41.6 ± 10.2 years, had a BMI of 30–35 kg/m2. Prospectively collected data were analyzed retrospectively. Factors assessed included disease duration, family history, medication use, remission, and biochemical indicators, including fasting plasma glucose, glycosylated hemoglobin (HbA1c), serum insulin, and C-peptide concentrations. Remission of T2DM was defined as HbA1c 2, mean waist circumference of 104.5 ± 8.2 cm, mean C-peptide concentration of 3.4 ± 1.2 ng/ml, and mean T2DM duration of 6.5 ± 3.1 years. Within 6 months of MGB, 95 % of these patients had attained HbA1c <7 %. Complete remission rates at 1, 2, and 7 years were 64, 66, and 53 %, respectively. Mean HbA1c decreased from 10.7 ± 1.5 % at baseline to 6.2 ± 0.5% at 1 year, 5.4 ± 1.2 % at 3 years, and 5.7 ± 1.8 % at 7 years. No deaths occurred, but two (1.6 %) patients experienced major complications. MGB provides good, long-term control of T2DM in patients with class I obesity. Early intervention results in higher remission rates.